Central Precocious Puberty: Treatment with Triptorelin 11.25 mg. (3rd May 2012)

• Record Type: Journal Article
• Authors: Chiocca, Elena; Dati, Eleonora; Baroncelli, Giampiero I.; Cassio, Alessandra; Wasniewska, Malgorzata; Galluzzi, Fiorella; Einaudi, Silvia; Cappa, Marco; Russo, Gianni; Bertelloni, Silvano
• Other Names: Adrian Thomas E. Academic Editor.
• Is Part Of: TheScientificWorldjournal. Volume 2012(2012)
• Publication Date: 2012-05-03
• Subjects: Science -- Periodicals; Technology -- Periodicals; Medicine -- Periodicals; 505
• DOI: 10.1100/2012/583751
• Languages: English
• ISSNs: 2356-6140

Abstract

Abstract : Background . Few data are available on quarterly 11.25 mg GnRH analog treatment in central precocious puberty (CPP). Aim . To assess the efficacy of triptorelin 11.25 mg in children with CPP. Patients . 17 patients (16 females) with CPP (7.9 ± 0.9 years) were treated with triptorelin 11.25 mg/90 days. Methods . Gonadotropins, basal-, and GnRH-stimulated peak, gonadal steroids, and pubertal signs were assessed at preinclusion and at inclusion visit, 3 months, 6 months, and 12 months of treatment. Results . At 3, 6, and 12 months, all patients had suppressed LH peak (<3 IU/L after GnRH stimulation), as well as prepubertal oestradiol levels. Mean LH peak values after GnRH test significantly decreased from 25.7 ± 16.5 IU/L at baseline to 0.9 ± 0.5 IU/L at M3 (P < 0.0001 ); they did not significantly changed at M6 and M12. Conclusions . Triptorelin 11.25 mg/90 days efficiently suppressed the pituitary-gonadal axis in children with CPP from first administration.